Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

Core Insights - Cidara Therapeutics is set to present late-breaking Phase 2 clinical data on its antiviral influenza candidate, CD388, at ID Week 2025 in Atlanta, GA from October 19-22, 2025 [1] Presentation Details - The presentation will focus on a randomized, placebo-controlled trial evaluating the safety and efficacy of CD388 for the prevention of illness due to Influenza A and B in healthy unvaccinated participants [2] - The session is titled "Extra, Extra! New Info on Treating and Preventing RSV and Influenza" and will take place on October 20, 2025, from 3:15 PM to 4:30 PM ET [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak® platform to develop drug-Fc conjugates (DFCs) that combine targeted small molecules or peptides with a human antibody fragment [3] - CD388 is designed as a long-acting antiviral for universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation [3] - The FDA granted Fast Track Designation to CD388 in June 2023, and positive top-line results from its Phase 2b NAVIGATE trial were announced in June 2025, with the Phase 3 ANCHOR trial initiated in September 2025 [3]